Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People who have been diagnosed with a high-grade blood cancer involving abnormal cells in the blood or bone marrow (called a high-grade myeloid neoplasm), but not a specific subtype called acute promyelocytic leukemia (APL); people with certain mixed-type acute leukemias may also be eligible
• People who have received some prior treatment to reduce abnormal cell counts before the study starts, including up to 2 doses of a specific medication (cytarabine) if their cancer was causing serious symptoms
• People who have previously received treatment for a lower-grade form of the same type of blood condition
• People whose general physical functioning, as rated by a standard medical scale (ECOG), falls within an acceptable range — the specific range depends on whether the person is under or over 75 years old (confirm with trial site)
• People who meet at least one of the following "unfit for intensive chemotherapy" criteria: a reduced physical functioning score; a history of heart failure or reduced heart pumping ability or stable chest pain; reduced lung function or breathlessness at rest or needing extra oxygen; moderately reduced kidney filtering ability; moderate liver impairment; or another health condition the treating doctor considers incompatible with intensive chemotherapy
• People with adequate heart function, as confirmed by tests such as a chest X-ray, heart tracing (ECG), and/or heart scan showing the heart is pumping at an acceptable level (confirm specific test requirements with trial site)
• People whose liver enzyme levels (AST and ALT) are within an acceptable range, unless the cancer itself is causing the elevation
• People whose bilirubin (a liver-related measure) is within an acceptable range, unless the cancer, a specific inherited condition, or blood cell breakdown is the cause
• People who agree to use effective contraception from the time of signing consent until at least 4 weeks after the last dose of the study treatment (applies to women who could become pregnant and to men)
• People living with HIV who are on effective treatment and have had an undetectable level of the virus within the past 6 months
• People who are able to understand the study and are willing to sign a written consent form

Who may not be able to join:

• People who have a known allergic or sensitivity reaction to cytarabine, anthracyclines, hypomethylating agents, or venetoclax (the types of medicines used in this trial)
• People with heart disease that causes symptoms such as tiredness, shortness of breath, or chest pain during ordinary everyday activity (classified as New York Heart Association Class 2 or higher)
• People who have an active, serious infection (viral, bacterial, or fungal) that is not well controlled and requires ongoing treatment
• People who have another serious illness that is likely to limit survival to less than 1 year
• People who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.